CLINICAL RESEARCH: MITRAL REGURGITATION
Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation
Timothy M. Sutton, MB, ChB*,
Ralph A. H. Stewart, MD ,*,
Ivor L. Gerber, MB, ChB,
Teena M. West, MSc,
A. Mark Richards, MD, DSc ,
Timothy G. Yandle, PhD and
Andrew J. Kerr, MB, ChB*
* Cardiology Department, Middlemore Hospital, Auckland, New Zealand
Cardiology Department, Green Lane Hospital, Auckland, New Zealand
Cardioendocrine Research Group, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
Manuscript received December 8, 2002;
revised manuscript received February 9, 2003,
accepted March 7, 2003.
* Reprint requests and correspondence: Dr. Ralph A. H. Stewart, Cardiology Department, Green Lane Hospital, Greenlane West, Epsom, Auckland 1003, New Zealand.
rstewart{at}adhb.govt.nz
OBJECTIVES: This paper will describe associations between plasma natriuretic peptide levels and the severity and symptoms of mitral regurgitation (MR).
BACKGROUND: A biochemical test that assisted grading of the severity of MR and the interpretation of symptoms would be of clinical value.
METHODS: Forty-nine patients with isolated MR and left ventricular (LV) ejection fractions (EFs) of >55% underwent transthoracic echocardiography, assessment of symptoms, and measurement of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and its amino-terminal portion, N-BNP.
RESULTS: The level of each natriuretic peptide rose with increasing severity of MR and with increases in left atrial (LA) dimensions (p < 0.001 for all comparisons), but no significant correlation existed between any natriuretic peptide and the LV dimensions or EF. Natriuretic peptide levels were higher in symptomatic MR (n = 16, BNP geometric mean 16.9 [95% confidence interval (CI) 13.3 to 21.4] pmol/l) compared with asymptomatic MR (n = 33, BNP 7.1 [95% CI 6.0 to 8.4] pmol/l, p < 0.001), and higher in asymptomatic MR than in normal controls (n = 100, BNP 5.3 [95% CI 4.8 to 5.8] pmol/l, p < 0.0001). These differences were similar for N-BNP and ANP and remained statistically significant (p < 0.05) after adjustment for echocardiographic measures of LV function and severity of MR. Both the sensitivity and the specificity for symptoms for the natriuretic peptides (area under receiver-operator characteristic curve for BNP = 0.90, N-BNP = 0.89, ANP = 0.89) were similar to the MR score (0.88) and greater than for LA dimension (0.81), vena contracta width (0.82), and LV end-systolic dimension (0.63).
CONCLUSIONS: Plasma natriuretic peptides levels increase with the severity of MR and are higher in symptomatic compared to asymptomatic patients, even when LV EF is normal.
|
Abbreviations and Acronyms
| | ANP | = atrial natriuretic peptide | | BNP | = brain natriuretic peptide | | CI | = confidence interval | | EF | = ejection fraction | | LA | = left atrial | | Ln | = natural logarithm | | LV | = left ventricular | | MI | = myocardial infarction | | MR | = mitral regurgitation | | N-BNP | = amino-terminal brain natriuretic peptide | | ROC | = receiver-operator characteristic |
|
This article has been cited by other articles:
|
|
|
|
 
R. W. Troughton and A. M. Richards
B-type natriuretic peptides and echocardiographic measures of cardiac structure and function.
J. Am. Coll. Cardiol. Img.,
February 1, 2009;
2(2):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Kerr, O. C. Raffel, G. A. Whalley, I. Zeng, and R. A. Stewart
Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation
Eur. Heart J.,
February 1, 2008;
29(3):
363 - 370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Baumgartner
Neurohormones in valvular heart disease: what can they tell us?
Eur. Heart J.,
February 1, 2008;
29(3):
290 - 292.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel
Natriuretic Peptides
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2357 - 2368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lee and T. H. Marwick
Assessment of subclinical left ventricular dysfunction in asymptomatic mitral regurgitation
Eur J Echocardiogr,
June 1, 2007;
8(3):
175 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Sivakumar, D Wellsted, K Parker, M Lynch, P Ghosh, and S A Khan
Utility of N terminal pro brain natriuretic peptide in elderly patients.
Postgrad. Med. J.,
March 1, 2006;
82(965):
220 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Davutoglu, A. Celik, M. Aksoy, Y. Sezen, S. Soydinc, and N. Gunay
Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease
Eur J Heart Fail,
June 1, 2005;
7(4):
532 - 536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Detaint, D. Messika-Zeitoun, J.-F. Avierinos, C. Scott, H. Chen, J. C. Burnett Jr, and M. Enriquez-Sarano
B-Type Natriuretic Peptide in Organic Mitral Regurgitation: Determinants and Impact on Outcome
Circulation,
May 10, 2005;
111(18):
2391 - 2397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Rodeheffer
Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?
J. Am. Coll. Cardiol.,
August 18, 2004;
44(4):
740 - 749.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, V. N. Tholakanahalli, A. G. Zenovich, S. A. Casey, D. Duprez, D. M. Aeppli, and J. N. Cohn
Usefulness of B-Type Natriuretic Peptide Assay in the Assessment of Symptomatic State in Hypertrophic Cardiomyopathy
Circulation,
March 2, 2004;
109(8):
984 - 989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Rahimtoola
The year in valvular heart disease
J. Am. Coll. Cardiol.,
February 4, 2004;
43(3):
491 - 504.
[Full Text]
[PDF]
|
|
|
|
